Exome Asset Management LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Exome Asset Management LLC reported 53 stock positions worth $202.4 million. Its top holding was Praxis Precision Medicines I (PRAX) at 8.5% of the portfolio, followed by Cogent Biosciences (COGT, 5.4%) and Guardant Health (GH, 5.0%). Compared with Q3 2025, it opened 20 new positions, sold out of 21, added to 5 and reduced 16. The biggest buy was a new position in Wave Life Sciences (WVE) and the biggest sale an exit from 89BIO (ETNB).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002011932
- Portfolio Value
- $202.4M (Q4 2025)
- SEC Filing
- 0001420506-26-000376 ↗ filed Feb 13, 2026
Holdings Value
Holdings 53 stocks · $202.4M
| PRAX Praxis Precision Medicines I | 8.46% | 58,122 | $17.1M | Reduce -43.0% |
| COGT Cogent Biosciences Inc. | 5.36% | 305,568 | $10.9M | Reduce -31.1% |
| GH Guardant Health Inc. | 4.95% | 98,182 | $10.0M | No change |
| IONS Ionis Pharmaceuticals Inc. | 4.55% | 116,515 | $9.2M | Reduce -11.1% |
| LLY Eli Lilly & Co. | 4.17% | 7,852 | $8.4M | No change |
| CYTK Cytokinetics Inc. | 3.92% | 124,749 | $7.9M | Reduce -12.4% |
| WVE Wave Life Sciences Ltd. | 3.54% | 421,488 | $7.2M | New |
| VERA Vera Therapeutics Inc. | 3.11% | 124,391 | $6.3M | Reduce -20.3% |
| BBIO Bridgebio Pharma Inc. | 3.05% | 80,723 | $6.2M | Reduce -39.4% |
| ELV Elevance Health Inc. | 2.98% | 17,191 | $6.0M | New |
| AZN Astrazeneca PLC-Spons ADR | 2.60% | 28,362 | $5.3M | No change |
| JAZZ Jazz Pharmaceuticals PLC | 2.23% | 26,494 | $4.5M | New |
| NTRA Natera Inc. | 2.11% | 18,650 | $4.3M | No change |
| IMVT Immunovant Inc. | 1.99% | 158,622 | $4.0M | No change |
| UHS Universal Health Services-B | 1.90% | 17,628 | $3.8M | Add +121.6% |
| UTHR United Therapeutics Corp. | 1.85% | 7,685 | $3.7M | Add +15.7% |
| AGIO Agios Pharmaceuticals Inc. | 1.84% | 136,942 | $3.7M | New |
| IRON Disc Medicine Inc. | 1.83% | 46,743 | $3.7M | Reduce -23.8% |
| ISRG Intuitive Surgical Inc. | 1.78% | 6,358 | $3.6M | No change |
| GKOS Glaukos Corp. | 1.76% | 31,471 | $3.6M | Add +15.9% |
| ELVN Enliven Therapeutics Inc. | 1.69% | 222,308 | $3.4M | New |
| CELC Celcuity Inc. | 1.69% | 34,289 | $3.4M | New |
| APLS Apellis Pharmaceuticals Inc. | 1.69% | 135,849 | $3.4M | New |
| TVTX Travere Therapeutics Inc. | 1.68% | 89,052 | $3.4M | Reduce -43.3% |
| DXCM Dexcom Inc. | 1.64% | 50,147 | $3.3M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.63% | 49,758 | $3.3M | Reduce -52.4% |
| CTMX Cytomx Therapeutics Inc. | 1.57% | 745,305 | $3.2M | No change |
| LQDA Liquidia Corp. | 1.55% | 91,148 | $3.1M | Reduce -3.3% |
| VSTM Verastem Inc. | 1.53% | 401,743 | $3.1M | New |
| ALMS Alumis Inc. | 1.41% | 292,250 | $2.9M | Reduce -0.2% |
| PEN Penumbra Inc. | 1.38% | 9,000 | $2.8M | No change |
| TXG 10X Genomics Inc. Class A | 1.32% | 163,658 | $2.7M | No change |
| IMCR Immunocore Holdings PLC-ADR | 1.32% | 76,750 | $2.7M | New |
| EWTX Edgewise Therapeutics Inc. | 1.23% | 100,046 | $2.5M | Reduce -42.3% |
| NXTC Nextcure Inc. | 1.16% | 165,000 | $2.3M | New |
| BLTE Belite Bio Inc. - ADR | 1.13% | 14,328 | $2.3M | New |
| WAY Waystar Holding Corp. | 1.12% | 68,969 | $2.3M | Add +47.1% |
| IRWD Ironwood Pharmaceuticals Inc. | 1.08% | 648,532 | $2.2M | New |
| KPTI Karyopharm Therapeutics Inc. | 1.07% | 295,541 | $2.2M | New |
| ADAG Adagene Inc.-ADR | 0.99% | 1,060,221 | $2.0M | New |
| NBP Novabridge Biosciences | 0.98% | 499,587 | $2.0M | Reduce -65.3% |
| UNH Unitedhealth Group Inc. | 0.95% | 5,835 | $1.9M | New |
| PALI Palisade Bio Inc. | 0.88% | 758,203 | $1.8M | New |
| UPB Upstream Bio Inc. | 0.87% | 64,845 | $1.8M | Add +24.8% |
| GOSS Gossamer Bio Inc. | 0.69% | 451,699 | $1.4M | No change |
| IKT Inhibikase Therapeutics Inc. | 0.61% | 600,000 | $1.2M | New |
| IQV Iqvia Holdings Inc. | 0.60% | 5,378 | $1.2M | New |
| THC Tenet Healthcare Corp. | 0.60% | 6,084 | $1.2M | Reduce -66.4% |
| CRBP Corbus Pharmaceuticals Holdi | 0.56% | 139,543 | $1.1M | Reduce -39.3% |
| FULC Fulcrum Therapeutics Inc. | 0.51% | 92,055 | $1.0M | Reduce -6.8% |
| ESTA Establishment Labs Holdings | 0.47% | 13,100 | $955K | No change |
| RAPT Rapt Therapeutics Inc. | 0.24% | 14,194 | $481K | New |
| ABUS Arbutus Biopharma Corp. | 0.18% | 75,484 | $363K | No change |
Options reported separately and not counted above: TRAVERE THERAPEUTICS INC puts ($2.9M), DISC MEDICINE INC puts ($1.3M), ULTRAGENYX PHARMACEUTICAL IN calls ($810K), ALUMIS INC puts ($519K), ALDEYRA THERAPEUTICS INC calls ($518K), PRECIGEN INC puts ($418K), SOLENO THERAPEUTICS INC puts ($328K).
Portfolio Sells Q3 2025 → Q4 2025
| ETNB 89BIO Inc. | Sold out | 0.00% | −2.66 |
| NBP Novabridge Biosciences | Reduce -65.3% | 0.98% | −2.61 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −2.48 |
| CVS CVS Health Corp. | Sold out | 0.00% | −2.17 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −2.16 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −1.84 |
| THC Tenet Healthcare Corp. | Reduce -66.4% | 0.60% | −1.83 |
| GERN Geron Corp. | Sold out | 0.00% | −1.68 |
| BBIO Bridgebio Pharma Inc. | Reduce -39.4% | 3.05% | −1.51 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −1.41 |
| CRBP Corbus Pharmaceuticals Holdi | Reduce -39.3% | 0.56% | −1.36 |
| CYTK Cytokinetics Inc. | Reduce -12.4% | 3.92% | −1.25 |
| COR Cencora Inc. | Sold out | 0.00% | −1.24 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −1.20 |
| SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27) | Sold out | 0.00% | −1.17 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -11.1% | 4.55% | −1.11 |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | Sold out | 0.00% | −1.08 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.96 |
| PRCT Procept Biorobotics Corp. | Sold out | 0.00% | −0.94 |
| INSP Inspire Medical Systems Inc. | Sold out | 0.00% | −0.91 |
| QURE Uniqure NV | Sold out | 0.00% | −0.85 |
| IRON Disc Medicine Inc. | Reduce -23.8% | 1.83% | −0.84 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.84 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −0.84 |
| TVTX Travere Therapeutics Inc. | Reduce -43.3% | 1.68% | −0.80 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -52.4% | 1.63% | −0.75 |
| EWTX Edgewise Therapeutics Inc. | Reduce -42.3% | 1.23% | −0.63 |
| MBX MBX Biosciences Inc. | Sold out | 0.00% | −0.61 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.20 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.12 |
| IMUX Immunic Inc. | Sold out | 0.00% | −0.10 |
| FULC Fulcrum Therapeutics Inc. | Reduce -6.8% | 0.51% | −0.09 |
| VERA Vera Therapeutics Inc. | Reduce -20.3% | 3.11% | +0.12 |
| LQDA Liquidia Corp. | Reduce -3.3% | 1.55% | +0.14 |
| ALMS Alumis Inc. | Reduce -0.2% | 1.41% | +0.64 |
| COGT Cogent Biosciences Inc. | Reduce -31.1% | 5.36% | +1.16 |
| PRAX Praxis Precision Medicines I | Reduce -43.0% | 8.46% | +4.89 |
Portfolio Buys Q3 2025 → Q4 2025
| WVE Wave Life Sciences Ltd. | New | 3.54% | +3.54 |
| ELV Elevance Health Inc. | New | 2.98% | +2.98 |
| JAZZ Jazz Pharmaceuticals PLC | New | 2.23% | +2.23 |
| AGIO Agios Pharmaceuticals Inc. | New | 1.84% | +1.84 |
| ELVN Enliven Therapeutics Inc. | New | 1.69% | +1.69 |
| CELC Celcuity Inc. | New | 1.69% | +1.69 |
| APLS Apellis Pharmaceuticals Inc. | New | 1.69% | +1.69 |
| DXCM Dexcom Inc. | New | 1.64% | +1.64 |
| VSTM Verastem Inc. | New | 1.53% | +1.53 |
| IMCR Immunocore Holdings PLC-ADR | New | 1.32% | +1.32 |
| NXTC Nextcure Inc. | New | 1.16% | +1.16 |
| BLTE Belite Bio Inc. - ADR | New | 1.13% | +1.13 |
| IRWD Ironwood Pharmaceuticals Inc. | New | 1.08% | +1.08 |
| KPTI Karyopharm Therapeutics Inc. | New | 1.07% | +1.07 |
| ADAG Adagene Inc.-ADR | New | 0.99% | +0.99 |
| UNH Unitedhealth Group Inc. | New | 0.95% | +0.95 |
| PALI Palisade Bio Inc. | New | 0.88% | +0.88 |
| UHS Universal Health Services-B | Add +121.6% | 1.90% | +0.82 |
| IKT Inhibikase Therapeutics Inc. | New | 0.61% | +0.61 |
| IQV Iqvia Holdings Inc. | New | 0.60% | +0.60 |
| GKOS Glaukos Corp. | Add +15.9% | 1.76% | +0.29 |
| RAPT Rapt Therapeutics Inc. | New | 0.24% | +0.24 |
| UPB Upstream Bio Inc. | Add +24.8% | 0.87% | +0.22 |
| UTHR United Therapeutics Corp. | Add +15.7% | 1.85% | +0.01 |
| WAY Waystar Holding Corp. | Add +47.1% | 1.12% | −0.06 |
Options Activity Q3 2025 → Q4 2025
| TRAVERE THERAPEUTICS INC | put | New | 74,700 | $2.9M |
| PPH Vaneck Pharmaceutical ETF | call | Sold out | 30,000 | $2.7Mbefore exit |
| TRAVERE THERAPEUTICS INC | call | Sold out | 110,000 | $2.6Mbefore exit |
| NOVO-NORDISK A S | call | Sold out | 35,000 | $1.9Mbefore exit |
| DISC MEDICINE INC | put | New | 16,000 | $1.3M |
| LIQUIDIA CORPORATION | put | Sold out | 53,000 | $1.2Mbefore exit |
| ARCTURUS THERAPEUTICS HLDGS | put | Sold out | 50,000 | $922Kbefore exit |
| MBX BIOSCIENCES INC | put | Sold out | 50,500 | $884Kbefore exit |
| ULTRAGENYX PHARMACEUTICAL IN | call | New | 35,200 | $810K |
| COGENT BIOSCIENCES INC | call | Sold out | 45,000 | $646Kbefore exit |
| CENTESSA PHARMACEUTICALS PLC | put | Sold out | 25,000 | $606Kbefore exit |
| PRAXIS PRECISION MEDICINES I | call | Sold out | 10,000 | $530Kbefore exit |
| MBX BIOSCIENCES INC | call | Sold out | 30,000 | $525Kbefore exit |
| ALUMIS INC | put | New | 53,200 | $519K |
| ALDEYRA THERAPEUTICS INC | call | New | 100,000 | $518K |
| ACAD Acadia Pharmaceuticals Inc. | put | Sold out | 20,000 | $427Kbefore exit |
| SOLENO THERAPEUTICS INC | put | New | 7,100 | $328K |
| KARYOPHARM THERAPEUTICS INC | put | Sold out | 48,100 | $315Kbefore exit |
| ATYR Atyr Pharma Inc. | call | Sold out | 40,000 | $29Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 52 | $162.1M | GH, PRAX, TGTX, COGT, IONS |
| Q1 2026 | 45 | $169.9M | PRAX, COGT, ELVN, IONS, GH |
| Q4 2025 | 53 | $202.4M | PRAX, COGT, GH, IONS, LLY |
| Q3 2025 | 54 | $151.4M | IONS, CYTK, BBIO, COGT, GH |
| Q2 2025Amended | 55 | $121.3M | ISHARES TR, BBIO, GH, GERN, IONS |
| Q1 2025Amended | 49 | $111.6M | BBIO, GH, GERN, AZN, CYTK |
| Q4 2024 | 58 | $132.9M | BBIO, LLY, GERN, HUM, GH |
| Q3 2024Amended | 59 | $147.9M | LLY, ASND, BBIO, GPCR, TGTX |
| Q2 2024Amended | 52 | $112.3M | LLY, SRPT, ONC, TGTX, CI |
| Q1 2024 | 53 | $116.8M | LLY, RDY, ONC, CI, ALPN |